Cargando…

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

Detalles Bibliográficos
Autores principales:	Korde, Neha, Mastey, Donna, Tavitian, Elizabet, Mailankody, Sham, Lesokhin, Alexander, Hassoun, Hani, Smith, Eric L., Lendvai, Nikoletta, Hultcrantz, Malin, Shah, Urvi, Tan, Carlyn, Lu, Sydney, Diamond, Benjamin, Salcedo, Meghan, Werner, Kelly, Chung, David J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar, Landau, Heather, Arcila, Maria, Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Derkach, Andriy, Devlin, Sean M., Giralt, Sergio A., Landgren, Ola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251553/ https://www.ncbi.nlm.nih.gov/pubmed/33661527 http://dx.doi.org/10.1002/ajh.26150

Ejemplares similares

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort study
por: Korde, Neha, et al.
Publicado: (2023)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls
por: Shah, Urvi A., et al.
Publicado: (2021)

P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
por: Akhlaghi, T., et al.
Publicado: (2022)

Nutrition perceptions, needs and practices among patients with plasma cell disorders
por: Malik, Maria A., et al.
Publicado: (2022)

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
por: Landgren, Ola, et al.
Publicado: (2016)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2020)

Author Correction: Accelerated single cell seeding in relapsed multiple myeloma
por: Landau, Heather J., et al.
Publicado: (2021)

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study
por: Usmani, Saad Z., et al.
Publicado: (2023)

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
por: Coffey, David G., et al.
Publicado: (2023)

Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease
por: Hofmann, Jonathan N, et al.
Publicado: (2017)

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients
por: Kazandjian, Dickran, et al.
Publicado: (2019)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT GENERATION SEQUENCING IN BONE MARROW IN A PHASE 2 STUDY OF DARATUMUMAB, CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE FOR MULTIPLE MYELOMA
por: Derman, B., et al.
Publicado: (2022)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
por: Landgren, O, et al.
Publicado: (2017)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Extreme body mass index and survival in newly diagnosed multiple myeloma patients
por: Shah, Urvi A., et al.
Publicado: (2023)

Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2019)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol
por: Svaton, Michael, et al.
Publicado: (2023)

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
por: Shao, Jianming, et al.
Publicado: (2023)

Di-Higgs results - twice the Higgs, twice the fun
por: Valente, Marco
Publicado: (2021)

Carfilzomib-Based Regimen and Cardiotoxicity in Multiple Myeloma: Incidence of Cardiovascular Events and Organ Damage in Carfilzomib-Dexamethasone versus Carfilzomib-Lenalidomide-Dexamethasone. A Real-Life Prospective Study
por: Astarita, Anna, et al.
Publicado: (2023)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Twice shy /
por: Francis, Dick
Publicado: (1983)

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
por: Huang, Phoebe A., et al.
Publicado: (2019)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
por: Shiomi, Daisuke, et al.
Publicado: (2013)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
por: Alsina, Melissa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rq5f2ah45rf94ng2ddmbccpj1a